[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100322647":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":32,"responsibleParty":50,"collaborators":53,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Control",null,"Defined as patients without a history of heart failure",{"label":13,"type":10,"description":14,"interventionNames":10},"Heart Failure w\u002FNormalEjectionFraction","Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 50%.",{"label":16,"type":10,"description":17,"interventionNames":10},"HeartFailure w\u002FReducedEjectionFraction","Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 50%.",[19],{"name":20,"affiliation":5,"role":21},"Hanna Gaggin, MD, MPH","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Abbie Macher, BS","CONTACT","617-643-6328","ajmacher@mgh.harvard.edu",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":31},"Laura Stockhausen, BS","617-724-1339","lstockhausen@mgh.harvard.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-71.05977,42.35843,{"lat":44,"lon":43},[47,49],{"name":48,"role":25,"phone":10,"phoneExt":10,"email":10},"Heather Jameson, PhD",{"name":20,"role":21,"phone":10,"phoneExt":10,"email":10},{"type":21,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Hanna Kim Gaggin","Assistant Professor of Medicine",[54],{"name":55,"class":56},"Roche Diagnostics GmbH","INDUSTRY","100322647","biomechanical-precision-medicine-registry-for-patients-with-and-without-heart-failure-100322647",false,"NCT03480633","Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure","Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study","PREFER-HF","Inclusion criteria for patients with HF:\n\n* 18 years and older\n* History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:\n\n  * NT-proBNP \\> 125 pg\u002FmL\n  * BNP \\> 35 pg\u002FmL\n  * Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI \\\u003C2.8 L\u002Fmin\u002Fm2\n  * LVEDP ≥ 15 mmHg\n  * Radiographic evidence of pulmonary edema\n  * Improvement in symptoms with diuretic initiation of increase\n  * CPET evidence of cardiac etiology of symptoms\n\nHFpEF: LVEF ≥ 50% HFrEF: LVEF \\\u003C50%\n\nExclusion criteria (for all patients, including both those with HFpEF and HFrEF):\n\n\\- End stage renal disease on dialysis",true,"ALL","18 Years",{"count":69,"type":70},3000,"ESTIMATED","50 Months","OBSERVATIONAL","In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.",[75,76,77,78,79],"Heart Failure With Normal Ejection Fraction","Heart Failure With Reduced Ejection Fraction","Heart Failure, Right Sided","Heart Failure With Mid Range Ejection Fraction","Cardiovascular Risk Factor",[81,82,83,84,85,86,87],"Heart failure","Precision medicine","High risk patients","Pathophysiology","Bioregistry","Biomarkers","Heart failure etiology","2025-12-02",{"date":90,"type":91},"2025-12-09","ACTUAL",{"date":93,"type":91},"2016-04-07",{"date":95,"type":70},"2027-10-06",{"name":5,"class":6},1]